Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Prelude Therapeutics Inc (PRLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update",
"Presentation"
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "D ENGINE DIFFERENTIATED PROGRAMS APPROACH CDK9 MCL1 SMARCA2 CDK4/6"
05/19/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Fenwick & West LLP",
"Prelude Therapeutics Announces Launch of Proposed Public Offering",
"Prelude Therapeutics Announces Pricing of Public Offering"
05/08/2023 8-K Quarterly results
03/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Open Market Sale AgreementSM, by and between Prelude Therapeutics Incorporated and Jefferies LLC",
"Opinion of Fenwick & West LLP"
03/15/2023 8-K Quarterly results
Docs: "Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024 Wilmington, DE – March 15, 2023 –",
"D ENGINE DIFFERENTIATED PROGRAMS APPROACH CDK9 MCL1 SMARCA2 CDK4/6",
"Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers WILMINGTON, Del. – March 15, 2023 –"
02/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
01/23/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS As Amended and Restated on January 19, 2023 PRELUDE THERAPEUTICS INCORPORATED AMENDED AND RESTATED BYLAWS"
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
11/14/2022 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update FDA clearance of two new INDs: PRT3789 and PRT3645 Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0 million as of September 30, 2022, expected to fund multiple data catalysts with a runway into the fourth quarter of 2024 WILMINGTON, Del.",
"PRT543, PRT811, PRT1419, PRT2527, PRT3645, PRT3789"
08/09/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "Prelude Therapeutics Reports Full Year 2021 Financial Results Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients"
03/09/2022 8-K Quarterly results
02/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation"
12/03/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients",
"Presentation"
09/17/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
07/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 15, 2021 Prelude Therapeutics Incorporated Delaware 001-39527 81-1384762 200 Powder Mill Road Wilmington, Delaware, 19803 Registrant's telephone number, including area code: 467-1280 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-co..."
06/22/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
01/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/04/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation dated January 2021"
11/10/2020 8-K Quarterly results
Docs: "Prelude Therapeutics Announces Third Quarter 2020 Financial Results - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M million -"
11/04/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amended and Restated Entrepreneur Client License Agreement, by and between Prelude Therapeutics Incorporated and Delaware Innovation Space, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy